Jae‐Hoon Kim
YOU?
Author Swipe
View article: Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes Open
Patient characteristics and analytical cohorts.
View article: Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes Open
Supplementary Methods
View article: Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes Open
Associations between gene expression and stage group and OS in MOC.
View article: Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes Open
Kaplan–Meier curves of OS in (A) main tumor groups (n = 582)—MBOT, MOC, LGI, and UGI; (B) patients with MOC by FIGO stage (n = 184); (C) patients with MOC by pattern of invasion in all stages (n = …
View article: Supplementary Figures S1-S13 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Supplementary Figures S1-S13 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes Open
Supplementary Figures S1-S13
View article: Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes Open
Schema of study numbers for each analysis to describe different cohort numbers due to pathology review and missing data. MOC, mucinous ovarian carcinoma; MBOT, mucinous borderline ovarian tumor; LGI, lower gastrointestinal; UGI, upper gast…
View article: Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes Open
Heat map of unsupervised clustering analysis. Contains all samples with a concordant pathology diagnosis (n = 497), with MOC grouped by FIGO stage. Labels show main clusters and diagnoses. Gene-expression values are normalized and l…
View article: Improvement of Menopausal Symptoms by <i>Beta vulgaris</i> , <i>Artemisia princeps</i> , and <i>Eleutherococcus senticosus</i> via Estrogen Pathway Activation in <scp>MCF</scp> ‐7 Cells and <scp>OVX</scp> Mice
Improvement of Menopausal Symptoms by <i>Beta vulgaris</i> , <i>Artemisia princeps</i> , and <i>Eleutherococcus senticosus</i> via Estrogen Pathway Activation in <span>MCF</span> ‐7 Cells and <span>OVX</span> Mice Open
Menopause, a natural transition marked by estrogen decline, is a growing public health concern because it impairs quality of life. Hormone replacement therapy (HRT) has been widely employed to alleviate menopausal symptoms, including osteo…
View article: Artificial urinary sphincter in neurogenic versus non-neurogenic SUI: Key differences and special considerations for neurogenic cases
Artificial urinary sphincter in neurogenic versus non-neurogenic SUI: Key differences and special considerations for neurogenic cases Open
View article: Evaluation of the safety and immunogenicity of a 9-valent human papillomavirus vaccine produced in Saccharomyces cerevisiae using a heating–chilling process for virus-like particle antigen assembly: a double-blind, randomized, placebo-controlled phase 1 clinical trial
Evaluation of the safety and immunogenicity of a 9-valent human papillomavirus vaccine produced in Saccharomyces cerevisiae using a heating–chilling process for virus-like particle antigen assembly: a double-blind, randomized, placebo-controlled phase 1 clinical trial Open
View article: Table S4 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Table S4 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Table S4 shows the top three unmet needs influencing treatment options across locations
View article: Table S6 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Table S6 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Table S6 shows access-related challenges reported by respondents in locations where bevacizumab is publicly reimbursed
View article: Figure S2 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Figure S2 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Figure S2 shows the proportion of mCC patients tested for various biomarkers
View article: Table S3 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Table S3 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Table S3 shows the importance of various factors influencing physicians' treatment choices for mCC patients across different locations
View article: Figure 1 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Figure 1 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Patient caseload based on staging by FIGO 2018. AU, Australia; CN, Chinese mainland; PH, Philippines; TW, Taiwan.
View article: Figure 2 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Figure 2 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Regional responses on factors influencing physicians’ treatment choices for patients with mCC. The importance of each factor was rated on a scale of 1 (not important at all) to 10 (extremely important), with scores categorized into the top…
View article: Figure S4 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Figure S4 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Figure S4 shows respondents' awareness of the public reimbursement status of bevacizumab in their locations
View article: Table 3 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Table 3 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Second-line treatment regimens received by patients with mCC
View article: Table S5 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Table S5 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Table S5 shows access-related challenges reported by respondents in locations where bevacizumab is not publicly reimbursed
View article: Data from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Data from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Despite treatment advances for metastatic cervical cancer (mCC), the Asia-Pacific region faces significant barriers in treatment accessibility, availability, and healthcare infrastructure. This study explored the treatment landscape and ba…
View article: Table S1 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Table S1 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Table S1 shows the different first-line treatment modalities received by mCC patients
View article: Figure S1 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Figure S1 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Figure S1 provides an overview of the respondent population across study locations
View article: Table 1 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Table 1 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Mapping of characteristics of patients with mCC based on physicians’ responses
View article: Figure 3 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Figure 3 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Physician-reported unmet needs affecting patients based on the treatment options available. Unmet needs were scored using a ranking system based on the level of impact: 1, biggest impact; 2, second biggest impact; 3, third biggest impact. …
View article: Table S7 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Table S7 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Table S7 shows the current (March 2025) reimbursement status of treatment regimens.
View article: Table 2 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Table 2 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
First-line treatment regimens received by patients with mCC
View article: Table S2 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Table S2 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Table S2 shows the patient profiles respondents considered for biomarker testing
View article: Figure S3 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Figure S3 from Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Figure S3 shows respondents' likelihood of testing their patients for biomarkers in the future
View article: Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers
Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers Open
Despite treatment advances for metastatic cervical cancer (mCC), the Asia-Pacific region faces significant barriers in treatment accessibility, availability, and healthcare infrastructure. This study explored the treatment landscape and ba…
View article: Unveiling the role of Metal–Support interactions in Ni catalysts for CO2-Free hydrogen and carbon nanotube production via methane pyrolysis
Unveiling the role of Metal–Support interactions in Ni catalysts for CO2-Free hydrogen and carbon nanotube production via methane pyrolysis Open